Neurocrine Biosciences, Inc. NBIX

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in Philadelphia.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the Company's executive management team as Chief Medical Officer (CMO), effective immediately. By mutual agreement, Sanjay Keswani, M.D., will depart the Company.

On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician’s scale says they moved less. The KINECT-PRO findings showed INGREZZA easing the daily burden of tardive dyskinesia in ways a rating scale alone never captures. The timing matters, because the data […]

Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciatio

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

Neurocrine Biosciences (NBIX) drew investor attention after the FDA accepted its Investigational New Drug application for a Phase 2 trial of NBI-1117567 in Alzheimer’s cognition, marking a fresh clinical milestone in its Nxera partnership. Despite the FDA news, Neurocrine Biosciences’ recent 30 day share price return is down 14.72%. However, the year to date share price return of 10.90% and 1 year total shareholder return of 12.22% point to momentum that has built over a longer horizon. Scan...

Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of NBI-1117567, an investigational oral muscarinic M1-preferring agonist for Alzheimer’s cognition, triggering a US$10,000,000 milestone payment to Nxera in Third Quarter Fiscal Year 2026. This IND milestone advances Neurocrine’s broader muscarinic receptor collaboration with Nxera, underscoring its push into Alzheimer’s-related cognitive symptoms alongside existing...

Neurocrine Biosciences stock has delivered a solid 5 year return while recent trading has been more mixed, and the current share price around US$156 still raises the question of how much value is already reflected. With the broader valuation checks leaning supportive and the market multiples screening as roughly in line with peers, investors are weighing whether the stock still offers an attractive entry point. Over the past 5 years Neurocrine Biosciences has returned 63.8%, which puts the...

Neurocrine Biosciences (NasdaqGS: NBIX) reported that the FDA has accepted its Investigational New Drug application for NBI-1117567 targeting Alzheimer's related cognition. The acceptance clears the way for a Phase 2 clinical study of NBI-1117567 in patients with cognitive symptoms linked to Alzheimer's disease. This IND milestone adds another clinical stage asset to Neurocrine Biosciences' development pipeline in a high unmet need area. This kind of progress in Alzheimer's drug development...

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone packageNxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd.

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems.